Uncovering the expression patterns and the clinical significance of miR-182, miR-205, miR-27a and miR-369 in patients with urinary bladder cancer.
Bladder cancer
Diagnosis
Epigenetic
Expression profiles
MicroRNA
Prognosis
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
19
08
2020
accepted:
17
10
2020
pubmed:
1
11
2020
medline:
25
5
2021
entrez:
31
10
2020
Statut:
ppublish
Résumé
Given the high recurrence and progression rates and the absence of reliable markers for early detection and prognosis prediction of patients with urothelial bladder cancer (BCa), the exploration of new biomarkers with high specificity is imperative. Mainly, microRNAs (miRNAs), which are involved in the initiation and the progression of BCa. Herein, the expression patterns of miR-182, miR-205, miR-27a and miR-369 were evaluated in patients with urothelial BCa. The expression levels of the miRNAs were investigated in 90 FFPE tissue samples (23 LG NMIBC, 44 HG NMIBC, 23 MIBC) and 10 non tumoral bladder tissues using TaqMan based RT-qPCR. Data analysis was performed using 2 Collectively, a selection of miRNAs was found to be aberrantly expressed in BCa suggesting a potential diagnostic value in BCa. In addition, the clinical value of miR-182 and miR-205 as potential prognosis biomarkers was highlighted. Indeed, our data provide additional insights into cancer biology. Further functional or target studies are mandatory to strengthen these findings.
Sections du résumé
BACKGROUND
BACKGROUND
Given the high recurrence and progression rates and the absence of reliable markers for early detection and prognosis prediction of patients with urothelial bladder cancer (BCa), the exploration of new biomarkers with high specificity is imperative. Mainly, microRNAs (miRNAs), which are involved in the initiation and the progression of BCa. Herein, the expression patterns of miR-182, miR-205, miR-27a and miR-369 were evaluated in patients with urothelial BCa.
METHODS AND RESULTS
RESULTS
The expression levels of the miRNAs were investigated in 90 FFPE tissue samples (23 LG NMIBC, 44 HG NMIBC, 23 MIBC) and 10 non tumoral bladder tissues using TaqMan based RT-qPCR. Data analysis was performed using 2
CONCLUSION
CONCLUSIONS
Collectively, a selection of miRNAs was found to be aberrantly expressed in BCa suggesting a potential diagnostic value in BCa. In addition, the clinical value of miR-182 and miR-205 as potential prognosis biomarkers was highlighted. Indeed, our data provide additional insights into cancer biology. Further functional or target studies are mandatory to strengthen these findings.
Identifiants
pubmed: 33128684
doi: 10.1007/s11033-020-05932-3
pii: 10.1007/s11033-020-05932-3
doi:
Substances chimiques
MIRN205 microRNA, human
0
MIRN27 microRNA, human
0
MIRN369 microRNA, human
0
MicroRNAs
0
Mirn182 microRNA, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8819-8830Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
doi: 10.3322/caac.21492
Cherif M, Chakroun M, Bouzouita A, Dimassi H, Ayed H, Derouiche A, Ben Slama MR, Chebil M (2016) Caractéristiques épidémiologiques du cancer de la vessie chez la femme en Tunisie. Afr J Urol 22(2):71–75. https://doi.org/10.1016/j.afju.2015.06.005
doi: 10.1016/j.afju.2015.06.005
Ratert N, Meyer HA, Jung M, Lioudmer P, Mollenkopf HJ, Wagner I, Miller K, Kilic E, Erbersdobler A, Weikert S, Jung K (2013) miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn 15(5):695–705. https://doi.org/10.1016/j.jmoldx.2013.05.008
doi: 10.1016/j.jmoldx.2013.05.008
pubmed: 23945108
Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Gontero P, Van Rhijn BWG, Mostafid AH, Palou J, Shariat SF (2018) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 73(1):111–122. https://doi.org/10.1016/j.eururo.2017.07.036
doi: 10.1016/j.eururo.2017.07.036
pubmed: 28867446
Liu C, Shi B, Hao C, Wang Q, Lv Q, Xing N, Shou J, Qu L, Gao Y, Qin C, Zhao J, Shou C (2016) Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer. Oncotarget 7(28):43432–43441. https://doi.org/10.18632/oncotarget.9468
doi: 10.18632/oncotarget.9468
pubmed: 27223068
pmcid: 5190035
Armand-Labit V, Pradines A (2017) Circulating cell-free microRNAs as clinical cancer biomarkers. Biomol Concepts 8(2):61–81. https://doi.org/10.1515/bmc-2017-0002
doi: 10.1515/bmc-2017-0002
pubmed: 28448269
Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447–461. https://doi.org/10.1016/j.eururo.2016.05.041
doi: 10.1016/j.eururo.2016.05.041
pubmed: 27324428
Andrew AS, Karagas MR, Schroeck FR, Marsit CJ, Schned AR, Pettus JR, Armstrong DA, Seigne JD (2019) MicroRNA dysregulation and non-muscle-invasive bladder cancer prognosis. Cancer Epidemiol Biomark Prev 28(4):782–788. https://doi.org/10.1158/1055-9965.EPI-18-0884
doi: 10.1158/1055-9965.EPI-18-0884
Lan H, Lu H, Wang X, Jin H (2015) MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed Res Int 2015:125094. https://doi.org/10.1155/2015/125094
doi: 10.1155/2015/125094
pubmed: 25874201
pmcid: 4385606
Xie Y, Ma X, Chen L, Li H, Gu L, Gao Y, Zhang Y, Li X, Fan Y, Chen J, Zhang X (2017) MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis. Sci Rep 7(1):5619. https://doi.org/10.1038/s41598-017-05801-3
doi: 10.1038/s41598-017-05801-3
pubmed: 28717125
pmcid: 5514092
Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, Reich O, Rouprêt M, Shariat SF, Zlotta AR (2011) Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 60(3):484–492. https://doi.org/10.1016/j.eururo.2011.05.053
doi: 10.1016/j.eururo.2011.05.053
pubmed: 21684071
Vosgha H, Ariana A, Smith RA, Lam AK (2018) miR-205 targets angiogenesis and EMT concurrently in anaplastic thyroid carcinoma. Endocr Relat Cancer 25(3):323–337. https://doi.org/10.1530/erc-17-0497
doi: 10.1530/erc-17-0497
pubmed: 29317480
Fu JH, Yang S, Nan CJ, Zhou CC, Lu DQ, Li S, Mu HQ (2018) MiR-182 affects renal cancer cell proliferation, apoptosis, and invasion by regulating PI3K/AKT/mTOR signaling pathway. Eur Rev Med Pharmacol Sci 22(2):351–357. https://doi.org/10.26355/eurrev_201801_14179
doi: 10.26355/eurrev_201801_14179
pubmed: 29424922
Wang B, Lv K, Chen W, Zhao J, Luo J, Wu J, Li Z, Qin H, Wong T-S, Yang W, Fu Q-L, Lei W (2016) miR-375 and miR-205 regulate the invasion and migration of laryngeal squamous cell carcinoma synergistically via AKT-mediated EMT. Biomed Res Int 2016:9652789. https://doi.org/10.1155/2016/9652789
doi: 10.1155/2016/9652789
pubmed: 28078305
pmcid: 5204095
Li XL, Hara T, Choi Y, Subramanian M, Francis P, Bilke S, Walker RL, Pineda M, Zhu Y, Yang Y, Luo J, Wakefield LM, Brabletz T, Park BH, Sharma S, Chowdhury D, Meltzer PS, Lal A (2014) A p21-ZEB1 complex inhibits epithelial–mesenchymal transition through the microRNA 183–96-182 cluster. Mol Cell Biol 34(3):533–550. https://doi.org/10.1128/MCB.01043-13
doi: 10.1128/MCB.01043-13
pubmed: 24277930
pmcid: 3911499
Suzuki HI (2018) MicroRNA control of TGF-β signaling. Int J Mol Sci 19(7):1901. https://doi.org/10.3390/ijms19071901
doi: 10.3390/ijms19071901
pmcid: 6073626
Fang F, Huang B, Sun S, Xiao M, Guo J, Yi X, Cai J, Wang Z (2018) miR-27a inhibits cervical adenocarcinoma progression by downregulating the TGF-βRI signaling pathway. Cell Death Dis 9(3):395. https://doi.org/10.1038/s41419-018-0431-2
doi: 10.1038/s41419-018-0431-2
pubmed: 29531222
pmcid: 5847584
Zeng Y, Zhu J, Shen D, Qin H, Lei Z, Li W, Huang JA, Liu Z (2016) Repression of Smad4 by miR-205 moderates TGF-β-induced epithelial–mesenchymal transition in A549 cell lines. Int J Oncol 49(2):700–708. https://doi.org/10.3892/ijo.2016.3547
doi: 10.3892/ijo.2016.3547
pubmed: 27279345
Kong WQ, Bai R, Liu T, Cai CL, Liu M, Li X, Tang H (2012a) MicroRNA-182 targets cAMP-responsive element-binding protein 1 and suppresses cell growth in human gastric adenocarcinoma. FEBS J 279(7):1252–1260. https://doi.org/10.1111/j.1742-4658.2012.08519.x
doi: 10.1111/j.1742-4658.2012.08519.x
pubmed: 22325466
Zhao X, Yang L, Hu J (2011) Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 30(1):55–55. https://doi.org/10.1186/1756-9966-30-55
doi: 10.1186/1756-9966-30-55
pubmed: 21569481
pmcid: 3120716
Feng D-D, Zhang H, Zhang P, Zheng Y-S, Zhang X-J, Han B-W, Luo X-Q, Xu L, Zhou H, Qu L-H, Chen Y-Q (2011) Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med 15(10):2164–2175. https://doi.org/10.1111/j.1582-4934.2010.01213.x
doi: 10.1111/j.1582-4934.2010.01213.x
pubmed: 21070600
pmcid: 4394226
Wang Z, Lai J, Wang Y, Nie W, Guan X (2013) The Hsa-miR-27a rs895819 (A>G) polymorphism and cancer susceptibility. Gene 521(1):87–90. https://doi.org/10.1016/j.gene.2013.02.042
doi: 10.1016/j.gene.2013.02.042
pubmed: 23524006
Hao GJ, Ding YH, Wen H, Li XF, Zhang W, Su HY, Liu DM, Xie NL (2017) Attenuation of deregulated miR-369-3p expression sensitizes non-small cell lung cancer cells to cisplatin via modulation of the nucleotide sugar transporter SLC35F5. Biochem Biophys Res Commun 488(3):501–508. https://doi.org/10.1016/j.bbrc.2017.05.075
doi: 10.1016/j.bbrc.2017.05.075
pubmed: 28511796
Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, Westra WH (2010) Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 16(2):610–619. https://doi.org/10.1158/1078-0432.ccr-09-2638
doi: 10.1158/1078-0432.ccr-09-2638
pubmed: 20068099
Le HB, Zhu WY, Chen DD, He JY, Huang YY, Liu XG, Zhang YK (2012) Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients. Med Oncol (Northwood, London, England) 29(5):3190–3197. https://doi.org/10.1007/s12032-012-0303-z
doi: 10.1007/s12032-012-0303-z
Cao P, Zhou L, Zhang J, Zheng F, Wang H, Ma D, Tian J (2013) Comprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma. Head Neck 35(5):720–728. https://doi.org/10.1002/hed.23011
doi: 10.1002/hed.23011
pubmed: 22605671
Friedman JM, Liang G, Liu CC, Wolff EM, Tsai YC, Ye W, Zhou X, Jones PA (2009) The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Can Res 69(6):2623–2629. https://doi.org/10.1158/0008-5472.can-08-3114
doi: 10.1158/0008-5472.can-08-3114
Hirata H, Ueno K, Shahryari V, Tanaka Y, Tabatabai ZL, Hinoda Y, Dahiya R (2012) Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS ONE 7(11):e51056. https://doi.org/10.1371/journal.pone.0051056
doi: 10.1371/journal.pone.0051056
pubmed: 23226455
pmcid: 3511415
Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, Vieillefond A, Zerbib M, Lidereau R, Debre B, Amsellem-Ouazana D, Bieche I (2013) microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer 132(11):2479–2491. https://doi.org/10.1002/ijc.27949
doi: 10.1002/ijc.27949
pubmed: 23169479
Wszolek MF, Rieger-Christ KM, Kenney PA, Gould JJ, Silva Neto B, Lavoie AK, Logvinenko T, Libertino JA, Summerhayes IC (2011) A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol 29(6):794-801.e791. https://doi.org/10.1016/j.urolonc.2009.08.024
doi: 10.1016/j.urolonc.2009.08.024
pubmed: 19945312
Wang G, Chan ES, Kwan BC, Li PK, Yip SK, Szeto CC, Ng CF (2012) Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer 10(2):106–113. https://doi.org/10.1016/j.clgc.2012.01.001
doi: 10.1016/j.clgc.2012.01.001
pubmed: 22386240
Baumann B, Acosta AM, Richards Z, Deaton R, Sapatynska A, Murphy A, Kajdacsy-Balla A, Gann PH, Nonn L (2019) Association of high miR-182 levels with low-risk prostate cancer. Am J Pathol 189(4):911–923. https://doi.org/10.1016/j.ajpath.2018.12.014
doi: 10.1016/j.ajpath.2018.12.014
pubmed: 30703341
pmcid: 6446228
Liu X, Xu T, Hu X, Chen X, Zeng K, Sun L, Wang S (2018) Elevated circulating miR-182 acts as a diagnostic biomarker for early colorectal cancer. Cancer Manag Res 10:857–865. https://doi.org/10.2147/cmar.s158016
doi: 10.2147/cmar.s158016
pubmed: 29731665
pmcid: 5927061
Zhang X, Ma G, Liu J, Zhang Y (2017) MicroRNA-182 promotes proliferation and metastasis by targeting FOXF2 in triple-negative breast cancer. Oncol Lett 14(4):4805–4811. https://doi.org/10.3892/ol.2017.6778
doi: 10.3892/ol.2017.6778
pubmed: 29085483
pmcid: 5649577
Medimegh I, Omrane I, Privat M, Uhrhummer N, Ayari H, Belaiba F, Benayed F, Benromdhan K, Mader S, Bignon I-J, Elgaaied AB (2014) MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: interaction with clinical outcome. PLoS ONE 9(11):e111877. https://doi.org/10.1371/journal.pone.0111877
doi: 10.1371/journal.pone.0111877
pubmed: 25369070
pmcid: 4219794
Kong W-Q, Bai R, Liu T, Cai C-L, Liu M, Li X, Tang H (2012b) MicroRNA-182 targets cAMP-responsive element-binding protein 1 and suppresses cell growth in human gastric adenocarcinoma. FEBS J 279(7):1252–1260. https://doi.org/10.1111/j.1742-4658.2012.08519.x
doi: 10.1111/j.1742-4658.2012.08519.x
pubmed: 22325466
Hu J, Lv G, Zhou S, Zhou Y, Nie B, Duan H, Zhang Y, Yuan X (2015) The downregulation of MiR-182 is associated with the growth and invasion of osteosarcoma cells through the regulation of TIAM1 expression. PLoS ONE 10(5):e0121175. https://doi.org/10.1371/journal.pone.0121175
doi: 10.1371/journal.pone.0121175
pubmed: 25973950
pmcid: 4431740
Ghorbanmehr N, Gharbi S (2019) miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer. Prostate J 79(1):88–95. https://doi.org/10.1002/pros.23714
doi: 10.1002/pros.23714
Adachi R, Horiuchi S, Sakurazawa Y, Hasegawa T, Sato K, Sakamaki T (2011) ErbB2 down-regulates microRNA-205 in breast cancer. Biochem Biophys Res Commun 411(4):804–808. https://doi.org/10.1016/j.bbrc.2011.07.033
doi: 10.1016/j.bbrc.2011.07.033
pubmed: 21787752
Drayton RM, Dudziec E, Peter S, Bertz S, Hartmann A, Bryant HE, Catto JW (2014) Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res 20(7):1990–2000. https://doi.org/10.1158/1078-0432.ccr-13-2805
doi: 10.1158/1078-0432.ccr-13-2805
pubmed: 24516043
pmcid: 3974662
Wang J, Guan X, Zhang Y, Ge S, Zhang L, Li H, Wang X, Liu R, Ning T, Deng T, Zhang H, Jiang X, Ba Y, Huang D (2018) Exosomal miR-27a derived from gastric cancer cells regulates the transformation of fibroblasts into cancer-associated fibroblasts. Cell Physiol Biochem 49(3):869–883. https://doi.org/10.1159/000493218
doi: 10.1159/000493218
pubmed: 30184548
Maghsudlu M, Farashahi Yazd E (2019) Increased expression of MiR-27a and MiR-24-2 in esophageal squamous cell carcinoma. J Gastrointest Canc. https://doi.org/10.1007/s12029-019-00232-x
doi: 10.1007/s12029-019-00232-x
Van der Auwera I, Limame R, van Dam P, Vermeulen PB, Dirix LY, Van Laere SJ (2010) Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer 103(4):532–541. https://doi.org/10.1038/sj.bjc.6605787
doi: 10.1038/sj.bjc.6605787
pubmed: 20664596
pmcid: 2939785
Yoneyama K, Ishibashi O, Kawase R, Kurose K, Takeshita T (2015) miR-200a, miR-200b and miR-429 are onco-miRs that target the PTEN gene in endometrioid endometrial carcinoma. Anticancer Res 35(3):1401–1410
pubmed: 25750291
Dong L, Zhang Z, Xu J, Wang F, Ma Y, Li F, Shen C, Liu Z, Zhang J, Liu C, Yi P, Yu J (2019) Consistency analysis of microRNA-arm expression reveals microRNA-369-5p/3p as tumor suppressors in gastric cancer. Mol Oncol 13(7):1605–1620. https://doi.org/10.1002/1878-0261.12527
doi: 10.1002/1878-0261.12527
pubmed: 31162777
pmcid: 6599845